Aggrenox

cardiac valve replacement, Ischemic Attack, Transient, Coronary Disease + 9 more
Treatment
6 FDA approvals
13 Active Studies for Aggrenox

What is Aggrenox

DipyridamoleThe Generic name of this drug
Treatment SummaryDipyridamole is a medication that blocks the absorption and breakdown of adenosine in red blood cells and in the cells that line blood vessels. It also makes prostacyclin, a drug that stops blood clots, work better.
Dipyridamoleis the brand name
Aggrenox Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Dipyridamole
Dipyridamole
1980
98

Approved as Treatment by the FDA

Dipyridamole, also known as Dipyridamole, is approved by the FDA for 6 uses like Postoperative Thromboembolism and cardiac valve replacement .
Postoperative Thromboembolism
cardiac valve replacement
Venous Thrombosis
Stroke
Used to treat Cerebrovascular Accident in combination with Acetylsalicylic acid
Stroke
Used to treat previous stroke in combination with Acetylsalicylic acid
Transient Ischemic Attack (TIA)
Used to treat Transient Ischemic Attack in combination with Acetylsalicylic acid

Effectiveness

How Aggrenox Affects PatientsDipyridamole is a medicine used to widen the blood vessels, stop blood clots, and help prevent stroke. It is usually taken together with other anticoagulant drugs such as warfarin to prevent blood clots in patients with valve or vessel problems. It can also be used to take pictures of the heart, stop platelets from sticking together, and used with aspirin to lower the risk of stroke.
How Aggrenox works in the bodyDipyridamole works to stop platelets from clumping together and forming clots by preventing the breakdown of compounds that inhibit platelet function. It also increases the amount of a compound in the platelets that stops them from sticking together. Finally, Dipyridamole directly triggers the release of another compound which further raises the amount of the inhibitor compound inside the platelets.

When to interrupt dosage

The proposed portion of Aggrenox is contingent upon the diagnosed condition, such as Thrombosis, previous stroke and Stroke. The amount of dosage will depend on the technique for delivery (e.g. Tablet, coated or Capsule) highlighted in the table hereunder.
Condition
Dosage
Administration
cardiac valve replacement
, 25.0 mg, 50.0 mg, 200.0 mg, 75.0 mg, 5.0 mg/mL, 100.0 mg, 150.0 mg
, Oral, Tablet - Oral, Tablet, Capsule, Capsule - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, coated, Tablet, coated - Oral, Injection, Injection - Intravenous, Intravenous, Solution, Solution - Intravenous, Injection, solution, Injection, solution - Intravenous, Liquid, Liquid - Intravenous, Capsule, extended release, Capsule, extended release - Oral, Tablet, extended release, Tablet, extended release - Oral
Ischemic Attack, Transient
, 25.0 mg, 50.0 mg, 200.0 mg, 75.0 mg, 5.0 mg/mL, 100.0 mg, 150.0 mg
, Oral, Tablet - Oral, Tablet, Capsule, Capsule - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, coated, Tablet, coated - Oral, Injection, Injection - Intravenous, Intravenous, Solution, Solution - Intravenous, Injection, solution, Injection, solution - Intravenous, Liquid, Liquid - Intravenous, Capsule, extended release, Capsule, extended release - Oral, Tablet, extended release, Tablet, extended release - Oral
Coronary Disease
, 25.0 mg, 50.0 mg, 200.0 mg, 75.0 mg, 5.0 mg/mL, 100.0 mg, 150.0 mg
, Oral, Tablet - Oral, Tablet, Capsule, Capsule - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, coated, Tablet, coated - Oral, Injection, Injection - Intravenous, Intravenous, Solution, Solution - Intravenous, Injection, solution, Injection, solution - Intravenous, Liquid, Liquid - Intravenous, Capsule, extended release, Capsule, extended release - Oral, Tablet, extended release, Tablet, extended release - Oral
Stroke
, 25.0 mg, 50.0 mg, 200.0 mg, 75.0 mg, 5.0 mg/mL, 100.0 mg, 150.0 mg
, Oral, Tablet - Oral, Tablet, Capsule, Capsule - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, coated, Tablet, coated - Oral, Injection, Injection - Intravenous, Intravenous, Solution, Solution - Intravenous, Injection, solution, Injection, solution - Intravenous, Liquid, Liquid - Intravenous, Capsule, extended release, Capsule, extended release - Oral, Tablet, extended release, Tablet, extended release - Oral
Heart Valve Prosthesis
, 25.0 mg, 50.0 mg, 200.0 mg, 75.0 mg, 5.0 mg/mL, 100.0 mg, 150.0 mg
, Oral, Tablet - Oral, Tablet, Capsule, Capsule - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, coated, Tablet, coated - Oral, Injection, Injection - Intravenous, Intravenous, Solution, Solution - Intravenous, Injection, solution, Injection, solution - Intravenous, Liquid, Liquid - Intravenous, Capsule, extended release, Capsule, extended release - Oral, Tablet, extended release, Tablet, extended release - Oral
Myocardial Perfusion Imaging
, 25.0 mg, 50.0 mg, 200.0 mg, 75.0 mg, 5.0 mg/mL, 100.0 mg, 150.0 mg
, Oral, Tablet - Oral, Tablet, Capsule, Capsule - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, coated, Tablet, coated - Oral, Injection, Injection - Intravenous, Intravenous, Solution, Solution - Intravenous, Injection, solution, Injection, solution - Intravenous, Liquid, Liquid - Intravenous, Capsule, extended release, Capsule, extended release - Oral, Tablet, extended release, Tablet, extended release - Oral
Venous Thrombosis
, 25.0 mg, 50.0 mg, 200.0 mg, 75.0 mg, 5.0 mg/mL, 100.0 mg, 150.0 mg
, Oral, Tablet - Oral, Tablet, Capsule, Capsule - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, coated, Tablet, coated - Oral, Injection, Injection - Intravenous, Intravenous, Solution, Solution - Intravenous, Injection, solution, Injection, solution - Intravenous, Liquid, Liquid - Intravenous, Capsule, extended release, Capsule, extended release - Oral, Tablet, extended release, Tablet, extended release - Oral
Anti-platelet Therapy
, 25.0 mg, 50.0 mg, 200.0 mg, 75.0 mg, 5.0 mg/mL, 100.0 mg, 150.0 mg
, Oral, Tablet - Oral, Tablet, Capsule, Capsule - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, coated, Tablet, coated - Oral, Injection, Injection - Intravenous, Intravenous, Solution, Solution - Intravenous, Injection, solution, Injection, solution - Intravenous, Liquid, Liquid - Intravenous, Capsule, extended release, Capsule, extended release - Oral, Tablet, extended release, Tablet, extended release - Oral
Ischemic Stroke
, 25.0 mg, 50.0 mg, 200.0 mg, 75.0 mg, 5.0 mg/mL, 100.0 mg, 150.0 mg
, Oral, Tablet - Oral, Tablet, Capsule, Capsule - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, coated, Tablet, coated - Oral, Injection, Injection - Intravenous, Intravenous, Solution, Solution - Intravenous, Injection, solution, Injection, solution - Intravenous, Liquid, Liquid - Intravenous, Capsule, extended release, Capsule, extended release - Oral, Tablet, extended release, Tablet, extended release - Oral
Stroke
, 25.0 mg, 50.0 mg, 200.0 mg, 75.0 mg, 5.0 mg/mL, 100.0 mg, 150.0 mg
, Oral, Tablet - Oral, Tablet, Capsule, Capsule - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, coated, Tablet, coated - Oral, Injection, Injection - Intravenous, Intravenous, Solution, Solution - Intravenous, Injection, solution, Injection, solution - Intravenous, Liquid, Liquid - Intravenous, Capsule, extended release, Capsule, extended release - Oral, Tablet, extended release, Tablet, extended release - Oral
Diagnostic Imaging
, 25.0 mg, 50.0 mg, 200.0 mg, 75.0 mg, 5.0 mg/mL, 100.0 mg, 150.0 mg
, Oral, Tablet - Oral, Tablet, Capsule, Capsule - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, coated, Tablet, coated - Oral, Injection, Injection - Intravenous, Intravenous, Solution, Solution - Intravenous, Injection, solution, Injection, solution - Intravenous, Liquid, Liquid - Intravenous, Capsule, extended release, Capsule, extended release - Oral, Tablet, extended release, Tablet, extended release - Oral
Transient Ischemic Attack (TIA)
, 25.0 mg, 50.0 mg, 200.0 mg, 75.0 mg, 5.0 mg/mL, 100.0 mg, 150.0 mg
, Oral, Tablet - Oral, Tablet, Capsule, Capsule - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, coated, Tablet, coated - Oral, Injection, Injection - Intravenous, Intravenous, Solution, Solution - Intravenous, Injection, solution, Injection, solution - Intravenous, Liquid, Liquid - Intravenous, Capsule, extended release, Capsule, extended release - Oral, Tablet, extended release, Tablet, extended release - Oral

Warnings

Aggrenox Contraindications
Condition
Risk Level
Notes
Pulse Frequency
Do Not Combine
Atrioventricular Block
Do Not Combine
Respiratory Sounds
Do Not Combine
There are 20 known major drug interactions with Aggrenox.
Common Aggrenox Drug Interactions
Drug Name
Risk Level
Description
Abrocitinib
Major
The risk or severity of bleeding and thrombocytopenia can be increased when Dipyridamole is combined with Abrocitinib.
Acebutolol
Major
Dipyridamole may increase the bradycardic activities of Acebutolol.
Albutrepenonacog alfa
Major
The therapeutic efficacy of Albutrepenonacog alfa can be decreased when used in combination with Dipyridamole.
Alprenolol
Major
Dipyridamole may increase the bradycardic activities of Alprenolol.
Alprostadil
Major
The risk or severity of hypotension and priapism can be increased when Dipyridamole is combined with Alprostadil.
Aggrenox Toxicity & Overdose RiskLow blood pressure may be a short-term side effect of this drug, but a medication to raise blood pressure may be prescribed if needed. The lowest toxic dose in rats was found to be greater than 6,000 mg/kg, while in dogs it was approximately 400 mg/kg. The lethal dose in rats is 8.4g/kg when taken orally.

Aggrenox Novel Uses: Which Conditions Have a Clinical Trial Featuring Aggrenox?

38 active trials are being conducted to assess the potential of Aggrenox in Postoperative Thromboembolism, Stroke and Thrombotic Disorders management.
Condition
Clinical Trials
Trial Phases
Coronary Disease
1 Actively Recruiting
Not Applicable
Venous Thrombosis
0 Actively Recruiting
cardiac valve replacement
0 Actively Recruiting
Heart Valve Prosthesis
0 Actively Recruiting
Transient Ischemic Attack (TIA)
2 Actively Recruiting
Phase 4, Not Applicable
Diagnostic Imaging
0 Actively Recruiting
Ischemic Stroke
0 Actively Recruiting
Ischemic Attack, Transient
0 Actively Recruiting
Anti-platelet Therapy
0 Actively Recruiting
Stroke
0 Actively Recruiting
Stroke
9 Actively Recruiting
Phase 4, Phase 1, Not Applicable
Myocardial Perfusion Imaging
1 Actively Recruiting
Phase 1

Aggrenox Reviews: What are patients saying about Aggrenox?

5Patient Review
10/14/2016
Aggrenox for Prevention of Blood Clots in the Brain
I had a TIA three years ago and was put on Clopidogrel. However, I developed mild numbness in my face after just fifteen days. So, I changed neurologists and he suggested Aggrenox. I had a headache for the first two days but then nothing else. I continued taking Aggrenox and now it's been three years with no further TIAs or side effects (besides mild acidity).
5Patient Review
7/30/2013
Aggrenox for Prevention of Blood Clots in the Brain
My doctor prescribed this in order to lower my HDL levels. It was successful, and I experienced some side effects; however, they eventually went away with continued use of the drug.
5Patient Review
1/9/2014
Aggrenox for Prevention of Blood Clots in the Brain
I had an ischemic stroke when I was 51, and Aggrenox has been a lifesaver. Not only have I not had any more strokes or TIA's, but I also haven't experienced any headaches. The only downside is that I sometimes bleed from my anus, but it's not too bad.
5Patient Review
1/27/2014
Aggrenox for Prevention of Blood Clots in the Brain
I've been on Aggrenox for six years now, and it has prevented any further mini-strokes (TSA) since I started taking it. I'm very pleased with the results and have experienced no negative side effects whatsoever.
5Patient Review
4/1/2013
Aggrenox for Prevention of Blood Clots in the Brain
View All Reviews

Patient Q&A Section about aggrenox

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is Aggrenox the same as aspirin?

"Aggrenox consists of aspirin and dipyridamole, which is another medication. Those who have had a stroke or TIA in the past generally take either aspirin or Aggrenox, but not both."

Answered by AI

What is the generic name for Aggrenox?

"The FDA approved the generic version of Aggrenox, aspirin/extended-release dipyridamole, on July 1, 2015. This medication is used to help prevent stroke in people who have had a previous "mini-stroke" or an actual ischemic stroke."

Answered by AI

What is the difference between Aggrenox and Plavix?

"Plavix protects you from blood clots after you have had a heart attack or surgery. It is a cheap, generic drug that is just as effective as more expensive options. Aggrenox prevents blood clots and stroke, but there are cheaper drugs available that work just as well."

Answered by AI

What is the medication Aggrenox used for?

"This medication is mean to prevent another stroke from happening to patients who have already had mini strokes or a single full stroke. The medication works by thinning the blood so that clots are less likely to form and cause another stroke."

Answered by AI

Clinical Trials for Aggrenox

Have you considered Aggrenox clinical trials? We made a collection of clinical trials featuring Aggrenox, we think they might fit your search criteria.
Have you considered Aggrenox clinical trials? We made a collection of clinical trials featuring Aggrenox, we think they might fit your search criteria.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top